The p53 tumour-suppressor protein exerts antiproliferative effects, including growth arrest and apoptosis, in response to various types of stress1. The activity of p53 is abrogated by mutations that occur frequently in tumours, as well as by several viral and cellular proteins1,2. The Mdm2 oncoprotein is a potent inhibitor of p53 (ref. 3). Mdm2 binds the transcriptional activation domain of p53 and blocks its ability to regulate target genes3,4 and to exert antiproliferative effects4–7. On the other hand, p53 activates the expression of the mdm2 gene1 in an autoregulatory feedback loop3. The interval between p53 activation and consequent Mdm2 accumulation defines a time window during which p53 exerts its effects8. We now report that Mdm2 also promotes the rapid degradation of p53 under conditions in which p53 is otherwise stabilized. This effect of Mdm2 requires binding of p53; moreover, a small domain of p53, encompassing the Mdm2-binding site, confers Mdm2-dependent detstabilization upon heterologous proteins. Raised amounts of Mdm2 strongly repress mutant p53 accumulation in tumour-derived cells. During recovery from DNA damage, maximal Mdm2 induction coincides with rapid p53 loss. We propose that the Mdm2-promoted degradation of p53 provides a new mechanism to ensure effective termination of the p53 signal.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Profilin 1 deficiency drives mitotic defects and reduces genome stability
Communications Biology Open Access 04 January 2023
Activating transcription factor 3 inhibits NF‑κB p65 signaling pathway and mediates apoptosis and cell cycle arrest in cervical cancer cells
Infectious Agents and Cancer Open Access 15 December 2022
ΔNp63α transcriptionally represses p53 target genes involved in the radiation-induced DNA damage response
Radiation Oncology Open Access 15 November 2022
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Gottlieb, T. & Oren, M. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287, 77–102 (1996).
Shen, Y. & Shenk, T. E. Viruses and apoptosis. Curr. Opin. Gene. Dev. 5, 105–111 (1995).
Picksley, S. M. & Lane, D. P. The p53–mdm2 autoregulatory feedback loop—a paradigm for the regulation of growth control by p53? Bioessays 15, 689–690 (1993).
Chen, J. D., Lin, J. Y. & Levine, A. J. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1, 141–142 (1995).
Chen, C. Y. et al. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl Acad. Sc. USA 91, 2684–2688 (1994).
Haupt, Y., Barak, Y. & Oren, M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15, 1596–1606 (1996).
Chen, J. D., Wu, X., Lin, J. Y. & Levine, A. J. mdm-2 inhibitis the Gl arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16, 2445–2452 (1996).
Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D. & Levine, A. J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl Acad. Sci. USA 90, 11623–11627(1993).
Barak, Y., Gottlieb, E., Juven-Gershon, T. & Oren, M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8, 1739–1749 (1994).
Lin, J. Y., Chen, J. D., Elenbaas, B. & Levine, A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235–1246 (1994).
Hinds, P. W. et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells-a comparison of the hot spot mutant phenotype. Cell Growth Diff. 1, 571–580 (1990).
Unger, T., Nau, M. M., Segal, S. & Minna, J. D. p53—a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11, 1383–1390 (1992).
Oren, M., Reich, N. C. & Levine, A. J. Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol. Cell. Biol. 2, 443–449 (1982).
Yonish-Rouach, E. et al. Induction of apoptosis by transiently transfected metabolically stable wt p53 is transformed cell lines. Cell Death Differ. 1, 39–47 (1994).
Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κBl precursor protein and the activation of NF-κB. Cell 78, 773–785 (1994).
Maki, C. J., Huibregtse, J. M. & Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56, 2649–2654 (1996).
Kubbutat, M. H. & Vousden, K. H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17, 460–468 (1997).
Gottlieb, E., Lindner, S. & Oren, M. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells. Cell Growth Diff. 7, 301–310 (1996).
Lane, D. P. The regulation of p53 function: Steiner award lecture. Int. J. Cancer 57, 623–627 (1994).
Bartek, J., Iggo, R., Gannon, J. & Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5, 893–899 (1990).
Martin, K. et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 575, 691–694 (1995).
Xiao, Z. X. et al. Interaction between the retinoblastoma protein and the oncoprotein Mdm2. Nature 375,694–698 (1995).
Momand, J. & Zambetti, G. P. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 12, 2279–2289 (1996).
Kastan, M. B., Onyekwere, O., Sindransky, D., Vogelstein, B. & Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304–6311 (1991).
Fiscella, M. et al. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8, 1519–1528 (1993).
Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495–505 (1993).
Otto, A. & Deppert, W. Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53. Oncogene 8, 2591–2603 (1993).
Jones, S. N., Roe, A. E., Donehower, L. A. & Bradley, A. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature 378, 206–208 (1995).
Monies de Oca Luna, R., Wagner, D. S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203–206 (1995).
Rights and permissions
About this article
Cite this article
Haupt, Y., Maya, R., Kazaz, A. et al. Mdm2 promotes the rapid degradation of p53. Nature 387, 296–299 (1997). https://doi.org/10.1038/387296a0
This article is cited by
BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network
Long-term p21 and p53 dynamics regulate the frequency of mitosis events and cell cycle arrest following radiation damage
Cell Death & Differentiation (2023)
Profilin 1 deficiency drives mitotic defects and reduces genome stability
Communications Biology (2023)
Coiled-coil domain containing 3 suppresses breast cancer growth by protecting p53 from proteasome-mediated degradation
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors
Current Hematologic Malignancy Reports (2023)
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.